drug
as of 2026-07-01omega-3 PUFAs
at a glance
DIETARY_SUPPLEMENT
Pre-approval / investigational in the US
Developed by Bambino Gesù Hospital and Research Institute
1 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
DIETARY_SUPPLEMENT
Indications
Investigational (via trials)
Trials
1
Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.
NCT02070211Phase 2, Phase 3Unknown
KOLs & investigators
1
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here